Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exploring the Pharmacokinetic/Pharmacodynamic Relationship of Relebactam (MK-7655) in Combination with Imipenem in a Hollow-Fiber Infection Model.
Wu J, Racine F, Wismer MK, Young K, Carr DM, Xiao JC, Katwaru R, Si Q, Harradine P, Motyl M, Bhagunde PR, Rizk ML. Wu J, et al. Among authors: rizk ml. Antimicrob Agents Chemother. 2018 Apr 26;62(5):e02323-17. doi: 10.1128/AAC.02323-17. Print 2018 May. Antimicrob Agents Chemother. 2018. PMID: 29507068 Free PMC article.
Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection.
Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, Rizk ML, Brown ML, Losada MC, Pedley A, Kartsonis NA, Paschke A. Lucasti C, et al. Among authors: rizk ml. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6234-43. doi: 10.1128/AAC.00633-16. Print 2016 Oct. Antimicrob Agents Chemother. 2016. PMID: 27503659 Free PMC article. Clinical Trial.
Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants.
Rhee EG, Rizk ML, Calder N, Nefliu M, Warrington SJ, Schwartz MS, Mangin E, Boundy K, Bhagunde P, Colon-Gonzalez F, Jumes P, Liu Y, Butterton JR. Rhee EG, et al. Among authors: rizk ml. Antimicrob Agents Chemother. 2018 Aug 27;62(9):e00280-18. doi: 10.1128/AAC.00280-18. Print 2018 Sep. Antimicrob Agents Chemother. 2018. PMID: 29914955 Free PMC article.
Erratum for Rhee et al., "Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of Relebactam, a β-Lactamase Inhibitor, in Combination with Imipenem and Cilastatin in Healthy Participants".
Rhee EG, Rizk ML, Calder N, Nefliu M, Warrington SJ, Schwartz MS, Mangin E, Boundy K, Bhagunde P, Colon-Gonzalez F, Jumes P, Liu Y, Butterton JR. Rhee EG, et al. Among authors: rizk ml. Antimicrob Agents Chemother. 2018 Nov 26;62(12):e02197-18. doi: 10.1128/AAC.02197-18. Print 2018 Dec. Antimicrob Agents Chemother. 2018. PMID: 30478180 Free PMC article. No abstract available.
Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.
Larson KB, Patel YT, Willavize S, Bradley JS, Rhee EG, Caro L, Rizk ML. Larson KB, et al. Among authors: rizk ml. Antimicrob Agents Chemother. 2019 May 24;63(6):e02578-18. doi: 10.1128/AAC.02578-18. Print 2019 Jun. Antimicrob Agents Chemother. 2019. PMID: 30962340 Free PMC article.
53 results